ArticleMedicine2015
Secondary Primary Malignancy Risk in Patients With Cervical Cancer in Taiwan: A Nationwide Population-Based Study.
Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.The Lancet. Infectious diseases · 2019Pooled it
- Second primary cancers among females with a first primary cervical, uterine and ovarian cancer: a population-based study in North Portugal.Cancer causes & control : CCC · 2026Article
- Second Malignancies Following Primary Cervical Cancer Diagnosis: Analysis of the SEER Database.Cureus · 2022Article
- Article
- Survival analysis of second primary malignancies after cervical cancer using a competing risk model: implications for prevention and surveillance.Annals of translational medicine · 2021Article
- Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms.MedComm · 2020Article
- Observational
- Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers.Journal of cancer research and clinical oncology · 2020Article
- Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers.Cancer epidemiology · 2020Article
- Clinical characteristics and risk of second primary lung cancer after cervical cancer: A population-based study.PloS one · 2020Article
- Cervical, anal and oral HPV detection and HPV type concordance among women referred for colposcopy.Infectious agents and cancer · 2020Article
- Familial Clustering, Second Primary Cancers and Causes of Death in Penile, Vulvar and Vaginal Cancers.Scientific reports · 2019Article
- Article
- Leiomyosarcoma of the Rectum as a Radiation-Induced Second Malignancy after Cervical Cancer Treatment: Case Report with Review of the Literature.Case reports in oncological medicine · 2019Article
- Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer.Gynecologic oncology · 2018Article
- Article
- Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports.Gynecologic oncology reports · 2017Article
- Triple malignancy in a single patient including a squamous cell carcinoma of the cervix, a colloid adenocarcinoma of the colon and a lung adenocarcinoma: A case report and literature review.International journal of surgery case reports · 2017Article
- Gastric metastases from gynaecologic tumors: case reports and review of the literature.Annals of translational medicine · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To evaluate the risk of secondary primary malignancy (SPM) in patients with cervical cancer using a nationwide population-based dataset.Patients newly diagnosed with cervical cancer between 1997 and 2011 were identified using Taiwan's National Health Insurance database. Patients with antecedent malignancies were excluded. Standardized incidence ratios (SIRs) for SPM were calculated by comparing with the cancer incidence in the general population. Risk factors for cancer development were analyzed using Cox proportional hazard models.During the 14-year study period (follow-up of 223,062 person-years), 2004 cancers developed in 35,175 patients with cervical cancer. The SIR for all cancers was 1.56 (95% confidence interval, 1.50-1.63, P < 0.001). SIRs for follow-up periods of >10, 5 to 10, 1 to 5, and <1 year were 1.37, 1.51, 1.34, and 2.59, respectively. After the exclusion of SPM occurring within 1 year of cervical cancer diagnosis, SIRs were significantly higher for cancers of the esophagus (2.05), stomach (1.38), colon, rectum, and anus (1.36); lung and mediastinum (2.28), bone and soft tissue (2.23), uterus (3.76), bladder (2.26), and kidneys (1.41). Multivariate analysis showed that age ≥60 was a significant SPM risk factor (hazard ratio [HR] 1.59). Different treatments for cervical cancer, including radiotherapy (HR 1.41) and chemotherapy (HR 1.27), had different impacts on SPM risk. Carboplatin and fluorouracil independently increased SPM risk in cervical cancer patients.Patients with cervical cancer are at increased risk of SPM development. Age ≥60 years, chemotherapy, and radiotherapy are independent risk factors. Carboplatin and fluorouracil also increased SPM risk independently. Close surveillance of patients at high risk should be considered for the early detection of SPMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.